WO2003107011A1 - スルホン酸化合物およびニトロ化合物を用いた測定方法 - Google Patents
スルホン酸化合物およびニトロ化合物を用いた測定方法 Download PDFInfo
- Publication number
- WO2003107011A1 WO2003107011A1 PCT/JP2003/005486 JP0305486W WO03107011A1 WO 2003107011 A1 WO2003107011 A1 WO 2003107011A1 JP 0305486 W JP0305486 W JP 0305486W WO 03107011 A1 WO03107011 A1 WO 03107011A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sample
- compound
- sulfonic acid
- measurement
- hemoglobin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
Definitions
- the present invention relates to a method for measuring an object to be measured in a sample using a redox reaction.
- glycated proteins in blood especially glycated hemoglobin in erythrocytes, reflect past histories of living blood glucose levels and are therefore important indicators in the diagnosis and treatment of diabetes.
- the glycated protein in such erythrocytes is measured using the redox reaction, for example, as described below.
- a sample prepared by lysing erythrocytes is prepared, and the lysed sample is treated with fructosyl amino acid oxidase (hereinafter, referred to as “FAOD”). generate.
- FOD fructosyl amino acid oxidase
- This amount of hydrogen peroxide corresponds to the amount of glycated protein.
- POD peroxidase
- a substrate that develops color by oxidation a color-developing substrate
- Allow a reduction reaction At this time, since the oxidation substrate develops color by oxidation, the amount of hydrogen peroxide can be measured by measuring the color development. You can know the amount of glycated protein.
- reducing substances such as ascorbic acid (AsA) and pyrilrubin are usually present in blood, and various reducing substances such as daltathione (GSH) are present in erythrocytes.
- these reducing substances may reduce the hydrogen peroxide, inhibit the redox reaction, or reduce the color of the reducing agent after the reducing agent has developed color. For this reason, there was a problem that it was difficult to accurately measure the amount of glycated protein in red blood cells.
- Japanese Patent Application Laid-Open No. 56-151358 discloses a method using a halogen oxide such as iodic acid and periodic acid as an oxidizing agent. 1 3 3 5 7
- JP-A-3-30697 disclose a method using a metal complex such as cobalt, iron, and cerium as an oxidizing agent.
- an object of the present invention is to use an object to be measured in a sample by a redox reaction. It is an object of the present invention to provide a measurement method which can obtain a highly reliable measurement value.
- a measurement method of the present invention is a method for measuring an object to be measured in a sample containing hemoglobin or a hemoglobin hydrolyzate by using a redox reaction, comprising: At least one of the oral compounds is added to the sample to eliminate the influence of the hemoglobin or hemoglobin degradation product contained in the sample.
- the present inventors (i) In the conventional method, the influence of a low molecular weight reducing substance such as AsA or GSH is excluded, but the effect of a high molecular weight reducing substance such as a protein is not excluded. Further, (ii) if the sample is treated with a tetrazolium compound, not only the low molecular weight reducing substance but also the high molecular weight reducing substance, in particular, hemoglobin and a hemoglobin decomposed product (hereinafter, both of which are referred to as “hemoglobin”) We have found that the effects of redox substances can be eliminated. The applicant has filed a separate application for this.
- the present inventors conducted further intensive research in order to eliminate the influence of hemoglobin without affecting the measurement system. As a result, they have found that by treating a sample with a sulfonate compound or a nitro compound, it is possible to prevent the effect of hemoglobin without affecting the measurement system, and reached the present invention. According to such a measuring method of the present invention, more accurate measurement can be performed at any time, and therefore, it is useful for various tests in clinical medicine and the like as described above.
- the measurement method of the present invention is a method for measuring an object to be measured in a sample by using a redox reaction, wherein at least one of a sulfonic acid compound and a nitro compound is added to the sample.
- a redox reaction wherein at least one of a sulfonic acid compound and a nitro compound is added to the sample.
- at least one of a sulfonic acid compound and a nitric compound is added to the sample.
- the influence of the hemagglutinating pin or hemoglobin hydrolyzate in the sample is eliminated, and then an oxidized substance or a reduced substance derived from the measurement target is generated, and the amount is measured by a redox reaction. It is preferable to determine the amount of the measurement object from the measured value.
- the substance to be added to eliminate the influence of hemoglobin may be, for example, either one of a sulfonic acid compound and a nitro compound, but since the influence can be further eliminated, both the compounds are added to the sample. Is preferred.
- the order of addition is not limited, and both may be added simultaneously or separately.
- examples of the sulfonic acid compound include:
- X is, for example, Na, K, Li, H, etc.
- N in R is, for example, in the range of 1 to 20. It is an enclosure.
- "H" may be substituted with an acyl group, a nitro group, a nitroso group, a phenyl group, an alkyl group, an alkyl ether group or the like.
- the sulfonic acid compound include, for example, sodium lauryl sulfate (hereinafter, referred to as “SLS”), sodium sulphate (hereinafter, referred to as “SDBS”), lithium lauryl sulfate (hereinafter, referred to as “SDBS”).
- SLS sodium lauryl sulfate
- SDBS sodium sulphate
- SDBS lithium lauryl sulfate
- LiLS 4-Aminoazobenzene-sodium 4'-sulfonate
- ABSA 4-Amino-4'-nitrostilbene-2,2'-sodium disulfonic acid
- ANDS 4-Amino-4'-nitrostilbene-2,2'-sodium disulfonic acid
- DADS 4,4'-Diazostilbenzene-2,2'-disulfonic acid disodium salt
- N-cyclohexyl-2-aminoethanesulfonic acid N-cyclohexyl-3-aminopropanesulfonate
- N-cyclohexyl-2-hydroxy-3-aminopropanesulfonate piperazine-1,4-bis (2-ethanesulfonic acid
- bathofena can be used, more preferably, SLS, SDBS, an L ILS.
- the nitro compound is not particularly limited, and examples thereof include a dinitrobenzene compound and a dinitrobenzene compound.
- These compounds, benzene ring, in addition to the nitro group, for example, one NH 2, - 0H, - C00H , - S0 3, - (CH 2) n CH 3 (n 2 ⁇ 9) substituent such as It is preferable to have a hydrophilic group as a substituent among these.
- the substituent include a halogen group, an ether group, and a phenyl group.
- nitro compound examples include, for example, 2,4-dinitrophenol (2,4-DNP), 2,5-dinitrophenyl, 2,6-dinitophylphenyl, 4,6-dinitro-2-methyl Phenol, 2-amino-4-nitrophenol, 2-amino No-5-nitrophenol, 2-amino-4-12-trophenol, p-nitrophenol (p-NP), 2,4-dinitroaniline (2,4-DNA), p-nitroaniline ( P-NA), sodium nitrite (NaN0 2), potassium nitrite (KN0 2), 4 - Amino - 4 '- to Nitorosuchiru', down - 2,2' sheet ', sulfonic acid disodium (hereinafter, the rANPSj ), Nitrobenzene, etc. can be used. When a sulfonic acid compound and a nitro compound are used in combination, the combination thereof is not particularly limited.
- the addition amount of the sulfonic acid compound or the nitro compound is not particularly limited, and is appropriately determined, for example, depending on the type of the sample, the amount of hemoglobin contained in the sample, the amount of other reduced substances, and the like. it can. Specific examples are shown below.
- a sulfonic acid compound or a two-mouthed compound for example, add either compound so that it will be in the range of 0.01 to 100 mo 1 per 1/1 of sample And more preferably in the range of 0.03 to 200 mo 1, particularly preferably 0.05 to 4 mo
- the oxidation-reduction reaction is a color-forming reaction in which an oxidizing enzyme reduces an oxidizing substance derived from the object to be measured and oxidizes a substrate (color-forming substrate) that develops color by oxidation. Is preferably a measure of the degree of color development by the color reaction. The measurement of the degree of color development can be performed, for example, by measuring absorbance at the detection wavelength of the substrate.
- color-developing substrate examples include N- (carbo'ximethi) reaminocarbo "nyl) -4,4, -bis (c" methylamino "), sodium X-nilamine (hereinafter referred to as” DA-64 ").
- DA-64 -bis (c" methylamino "), sodium X-nilamine
- Mouth pill -4, 4,,, 4, , -Triaminotriphenylmethane hexasote ', dimethyl salt (hereinafter referred to as "TPM-PS"), ⁇ , ⁇ , ⁇ ', ⁇ ', ⁇ ', ⁇ , '-hexa -3-sulfofol-propyl) -4, 4 ', 4' '-Triaminotrifyl-nylmethane dexamethasium salt (hereafter referred to as ⁇ -OSJ), 10- (Carho', xymethylaminocarho ') , Nil) 3,7-bis (methylamino) phenothiazine sodium salt (hereinafter referred to as “DA-67”), 10- (methylaminoamino "Nil) 3,7-bis (methylaminohafenothiacin) (hereinafter referred to as” MCDP "), 10- (carbo ', xya
- Examples of the above-mentioned tricker reagent include phenol, a phenol derivative, aniline derivative, naphthol, naphthol derivative, naphthylamine, naphthylamine derivative and the like.
- Examples of the compound to be combined with the above-mentioned Tinder reagent include, in addition to the above 4-aminoantipyrine, for example, an aminoantipyrine derivative, vanillin diamine sulfonic acid, methylamine Lupenzthiazolinone hydrazone (MBTH),
- SMBTH Suthiazolinone hydrazone
- the chromogenic substrate exemplified above usually has an absorption at 400 nm or more, when a tetrazolium compound as described above having an absorption at 400 nm is also used, the measured value depends on the presence of the tetrazolium compound. An error could occur. However, since the exemplified sulfonic acid compounds and nitro compounds do not absorb at more than 400 nm, there is no possibility that an error will occur in the absorbance measurement even when used together with these chromogenic substrates.
- the combination of these color-forming substrates with the sulfonic acid compound and the nitro compound is not particularly limited, but the following combinations are preferable, for example, because the color-forming reaction is performed with high accuracy. The reason why the accuracy of the color reaction can be improved according to the combination of the chromogenic substrate with the sulfonic acid compound and the nitro compound is unknown.
- the chromogenic substrate is M-64, a combination of a Trinder reagent and 4-aminoantipyrine, etc.
- SLS, SDBS, and LiLS as the oxidized compound
- 2,4-DNA, 2,4-DNP, PNA, and PNP as the nitro compound.
- the chromogenic substrate is TPM-PS, TPM-OS, M-67, MCDP, MMX, or the like
- a sulfonic acid compound to the sample, and more preferably, to add the sulfonic acid compound to the sample. Both of the mouth compounds are added.
- the oxidizing substance derived from the measurement object is preferably hydrogen peroxide, and the oxidase is preferably peroxidase.
- the measurement sample is not particularly limited.
- the measurement object is not particularly limited as long as it utilizes an oxidation-reduction reaction, and examples thereof include whole blood components, red blood cell components, plasma components, and serum components. And preferably an intraerythrocyte component.
- glycated proteins such as glycated hemoglobin and glycated albumin, glycated peptides, glycated amino acids, glucose, uric acid, cholesterol, creatinine, sarcosine and glycerol, and more preferably glycated proteins.
- glycated proteins such as glycated hemoglobin and glycated albumin
- glycated peptides such as glycated albumin
- glycated peptides such as glycated amino acids, glucose, uric acid, cholesterol, creatinine, sarcosine and glycerol
- glycated proteins such as glycated hemoglobin and glycated albumin
- glycated peptides such as glycated albumin
- glycated amino acids such as glucose, uric acid, cholesterol, creatinine, sarcosine and glycerol
- the measurement target is a glycated protein
- hydrogen peroxide is generated as an acid compound substance derived from the measurement target by causing FAOD to act on the glycated protein.
- the saccharified portion of the saccharified protein is oxidatively decomposed by FAOD, generating hydrogen peroxide.
- glycated amines such as the glycated peptides and glycated amino acids also cause FAOD to act.
- the glycated protein or glycated peptide is preferably treated with a protease before the FAOD treatment, if necessary.
- the FAOD is a FAOD that catalyzes a reaction represented by the following formula (1). It is preferable that
- R 1 represents a hydroxyl group or a residue (sugar residue) derived from a sugar before a saccharification reaction.
- the sugar residue (R 1 ) is an aldose residue when the sugar before the reaction is aldose, and is a ketose residue when the sugar before the reaction is ketose.
- the sugar residue (R 1 ) is a glucose residue (aldose residue).
- This sugar residue (R 1 ) is, for example,
- n is an integer of 0-6.
- R 2 is not particularly limited.
- a glycated amino acid a glycated peptide or a glycated protein
- ⁇ amino group
- other amino groups are glycated. Is different.
- R 2 is an amino acid residue or a peptide residue represented by the following formula (2).
- R 3 represents an amino acid side chain group.
- R 4 represents a hydroxyl group, an amino acid residue or a peptide residue, and can be represented by the following formula (3), for example.
- n is an integer of 0 or more.
- R 3 represents an amino acid side chain group as described above.
- R 5 represents a portion other than the glycated amino group in the amino acid side chain group. .
- R 5 represents a portion other than the glycated amino group in the amino acid side chain group.
- R 5 is
- R 6 is hydrogen, an amino acid residue or a peptide residue, and can be represented by the following formula (5), for example.
- n is an integer of 0 or more, and R 3 represents an amino acid side chain group as described above.
- R 7 represents a hydroxyl group, an amino acid residue or It is a peptide residue and can be represented by, for example, the following formula (6).
- n is an integer of 0 or more, and R 3 represents an amino acid side chain group as described above. ⁇ (NH— CHR 3 -CO) n -OH... (6)
- the whole blood is directly lysed, or a blood cell fraction is separated from the whole blood by a conventional method such as centrifugation and lysed to prepare a hemolyzed sample.
- the hemolysis method is not particularly limited, and examples thereof include a method using a surfactant, a method using ultrasonic waves, and a method using a difference in osmotic pressure. Among them, the method using the surfactant is preferable because of the simplicity of the operation and the like.
- the surfactant examples include e. Rigid xyethylene-p-butyl octylphenyl: C-ter (Triton-based surfactant, etc.), e. Lioxyethylene 'norbitan alkyl ester (Tween surfactant etc.), e. Non-ionic surfactants such as polyoxyethylene alkyl ethers (Brij-based surfactants and the like) can be used, and specifically, for example, Triton X-100, Tween-20, B rij 35 and the like.
- the treatment conditions with the surfactant are usually such that when the blood cell concentration in the treatment solution is 1 to 10% by volume, the surface activity is adjusted so that the concentration in the treatment solution is 0.01 to 5% by weight.
- a sulfonic acid compound and a nitro compound is added to the hemolyzed sample, and the hemolyzed sample is pretreated.
- Either one of the sulfonic acid compound and the two-mouthed compound may be used, or both may be added. However, it is preferable that the sulfonic acid compound and the two-mouthed compound are appropriately determined depending on the type of the chromogenic substrate used in the subsequent step as described above.
- the amount of addition is not particularly limited, and the above-described addition ratio can be used.
- the concentration of the nitro compound is in the range of 0.05 to 500 mmo1 / L, preferably 0.2 to 10 mm01 / L. ZL range.
- the concentration of the sulfonic acid compound is in the range of 0.05 to 20 Ommo 1 / L, preferably 0.2 to 40 Omo 1 ZL. Range.
- the amount of addition is not particularly limited, and examples thereof include the above-described addition ratio.
- the sulfonic acid compound concentration is in the range of 0.05 to 20 Ommo 1 ZL
- the nitro compound concentration is in the range of 0.05 to 25 Ommo 1 ZL.
- the sulfonic acid compound concentration is preferably in the range of 0.2 to 40 mmol ZL
- the nitro compound concentration is in the range of 0.1 to 50 mmol / L.
- the sulfonic acid compound and the nitro compound may be used as they are, but are preferably used as a sulfonic acid compound solution or a nitro compound solution dissolved in a solvent from the viewpoint of simplicity of operation and processing efficiency. .
- the concentration of each of the above-mentioned solutions can be appropriately determined depending on the type and the like.
- the sulfonic acid compound solution is in the range of 5 to 100 mmo 1 ZL, preferably 5 to 400 mmo 1 ZL
- the nitro compound The solution is 0.5- It is in the range of 10 Ommo1 / L, preferably in the range of 1 to 50 mmo1 / L.
- the solvent for example, distilled water, physiological saline, buffer, or the like can be used.
- As the buffer for example, a buffer described below can be used. In addition, these two compounds may be used alone or in combination of two or more.
- This pretreatment is usually performed in a buffer solution.
- a buffer solution for example, an amine buffer, a phosphate buffer, a borate buffer, and a good buffer such as MOPS, CHES, CAPS, and CAPSO can be used.
- the buffer for the amine-based buffer include glycine, ethylamine, getylamine, methylamine, dimethylamine, trimethylamine, trishydroxyaminomethane, triethanolamine, glycinamide and the like.
- the pH of the buffer is preferably in the range of 7 to 12, more preferably: in the range of 8 to 11, particularly preferably in the range of 8 to 10.
- the conditions for this pretreatment are not particularly limited, but are usually in a temperature range of 10 to 37 ° C and a treatment time in a range of 10 seconds to 60 minutes.
- the pretreated hemolyzed sample is subjected to protease treatment. This is to make it easier for the FAOD used in the subsequent processing to act on the measurement object.
- the type of the protease is not particularly limited, and for example, protease K, subtilisin, trypsin, aminopeptidase, meta-oral protease, and the like can be used. Protease treatment conditions are appropriately determined depending on the type of protease used, the type of glycated protein to be measured, its concentration, and the like.
- the pretreated hemolyzed sample is treated using proteases as the protease
- usually the proteases in the reaction solution are used.
- This protease treatment is usually performed in a buffer solution.
- the buffer for example, the same buffer as in the pretreatment can be used.
- the decomposition product obtained by the protease treatment is treated with the FAOD. This FAOD treatment catalyzes the reaction represented by the above formula (1).
- This FAOD treatment is preferably performed in a buffer as in the protease treatment.
- the treatment conditions are appropriately determined depending on the type of FAOD used, the type of glycated protein to be measured, its concentration, and the like.
- the FAOD concentration in the reaction solution is 50 to 50,000 U / L
- blood cell concentration in the reaction solution 0.01 to 1% by volume
- reaction temperature 15 to 37 ° C
- reaction time 1 to 60 minutes
- the type of the buffer is not particularly limited, and the same buffer as used in the protease treatment can be used.
- the hydrogen peroxide generated by the FAOD treatment was converted to POD and It is measured by an oxidation-reduction reaction using the coloring substrate.
- the oxidation-reduction reaction is usually performed in a buffer, and the conditions are appropriately determined depending on the concentration of the generated hydrogen peroxide and the like.
- the P00 concentration in the reaction solution is 10 to 100,000 IU / L
- the chromogenic substrate concentration is 0.005 to 3 Ommo
- the reaction temperature is 15 to 37
- the reaction time is 0, ⁇ 30 minutes
- the buffer is not particularly limited, and for example, the same buffer as used in the above-described protease treatment, FAD treatment and the like can be used.
- the amount of hydrogen peroxide can be measured by measuring the degree of color development (absorbance) of the reaction solution with a spectrophotometer. Then, the amount of glycated protein in the sample can be determined using the hydrogen peroxide concentration and the calibration curve and the like.
- the amount of hydrogen peroxide can be measured by, for example, an electrical method in addition to the enzymatic method using the POD or the like.
- the pretreatment step with the sulfonic acid compound or the nitro compound is not particularly limited as long as the oxidation reduction reaction does not substantially occur, as described above. Therefore, it is preferable to perform the treatment before the FAOD treatment.
- each processing step may be performed separately as described above. For example, there are processing steps that may be performed simultaneously in the following combinations.
- the addition order of the sulfonic acid compound and the nitro compound and the addition order of the FAOD, POD and the chromogenic substrate are not particularly limited. According to such a method, by contacting a sulfonic acid compound or a nitro compound with the sample, only a low-molecular-weight reducing substance such as GSH, AsA, dithiothreitol, cysteine, and N-acetyl-cysteine can be used. In particular, the effects of hemoglobin and hemoglobin degradation products as reducing substances can be sufficiently eliminated.
- the measurement can be performed with high accuracy without affecting the oxidation-reduction reaction or the absorbance measurement.
- an oxidizing agent or an enzyme may be further used in combination.
- examples thereof include halogen oxides such as sodium acetate, iodic acid, and periodic acid, EDTA-Fe, and the like.
- the enzyme for example, ascorbate oxidase, bilirubin oxidase, and the like can be used.
- the addition amount of such an oxidizing agent is, for example, in the range of 0.001 to 0.1 mg per 11 samples.
- the measurement object is not particularly limited as long as it utilizes a redox reaction.
- a glycated protein as described above, a glycated peptide, a glycated amino acid, glucose, cholesterol, Uric acid, creatinine, sarcosine, glycerol and the like.
- hydrogen peroxide When hydrogen peroxide is generated to measure the amount of each of the measurement objects, for example, glucose is glucose oxidase, and cholesterol is Cholesterol oxidase on the roll, pericase on the uric acid, sarcosine oxidase on the creatinine, sarcosine oxidase on the sarcosine, glycerol oxidase on the glycerol, and hydrogen peroxide. Should be generated.
- the method for measuring the amount of hydrogen peroxide can be performed in the same manner as described above.
- the glycated peptide and glycated amino acid can be measured, for example, in the same manner as in the measurement of the glycated protein.
- the measurement target is treated with the sulfonic acid compound or the nitro compound, a reducing substance derived from the measurement target is generated, and the amount is measured by an oxidation-reduction reaction.
- the measurement can be performed as described below.
- the measurement object is glucose
- a reducing substance such as NADH or NADPH is generated using glucose dehydrogenase in the presence of NAD + or NADP +.
- NAD H and NAD PH which are reducing substances derived from the measurement object, are measured by, for example, redox reaction using diaphorase and a substrate that develops color by reduction.
- the amount of the measurement target in the sample can be determined using the concentration of the reducing substance derived from the measurement target and the calibration curve.
- the measurement target is cholesterol
- cholesterol dehydrogenase can be used
- the measurement target is sarcosine
- sarcosine dehydrogenase can be used.
- the substrate that develops color by the reduction is not particularly limited, and for example, the above-described chromogenic tetrazolium compound, 2,6-dichlorophenol and phenol may be used.
- a hemoglobin sample containing fructosyl valine (hereinafter referred to as “FV”) was treated with a sulfonic acid compound and a nitro compound using TPM-PS as a chromogenic substrate, and the FV amount was measured. It is.
- the following shows the samples, reagents and methods used.
- the hemoglobin frozen product was thawed with purified water to prepare a 50 gZL hemoglobin solution.
- FV was produced according to Japanese Patent Application Laid-Open No. 2-69644, and dissolved in purified water to prepare a 1 mM FV solution. Then, the hemoglobin solution 371, the FV solution 601, and purified water 2031 were mixed to prepare a measurement sample.
- MOPS- MOPSNa buffer ( ⁇ 9.4) 15 mM
- the sulfonic acid compound of the first reagent is SLS (manufactured by Nacalai Tesque), SDBS (manufactured by Wako Pure Chemical), AB SA (Tokyo Chemical) ), ANDS (Tokyo Kasei) and DADS (Tokyo Kasei) were used, respectively.
- SLS manufactured by Nacalai Tesque
- SDBS manufactured by Wako Pure Chemical
- AB SA Tokyo Chemical
- ANDS Tokyo Kasei
- DADS Tokyo Kasei
- MOPS-MOPS ⁇ buffer pH6.5
- MOPS-MOPS ⁇ buffer pH6.5
- the absorbance was measured in the same manner as in the above example, except that the sulfonic acid compound of the first reagent and the double-mouthed compound of the second reagent were not added.
- the addition amount of the sulfonic acid compound per 1 L of the sample was 0.189 mol, 0.378 zmol, and 0.38 mol.
- the amount was 755 ⁇ mo1
- the addition amount of the nitro compound was 3.46 mo1.
- Example 1 1-2 SLS (6.4) 2,4-DNA (0.9) 1 54 1-3 SLS (12.8) 2,4-DNA (0.9) 1 6 0 1-4 SDBS (6.4) 2, 4-DNA (0.9) 1 2 1 1-5 SLS (6.4) 1 54 1-6 ABSA (6.4) 1 3 2 1-7 ANDS (6.4) 1 1 3 1-8 DADS (6.4) 1 24 Comparative Example 1 3 0 As shown, as in Example 1, the use of various sulfonic acid compounds or the combined use of these with a nitro compound increased the absorbance indicating the amount of FV in the sample as compared to the comparative example. From this result, it can be seen that according to the present example, the effect of hemoglobin in the sample was eliminated by the sulfonic acid compound and the two-mouthed compound.
- a hemoglobin sample containing FV was treated with a sulfonic acid compound and a nitro compound using DA-64 as a chromogenic substrate, and the amount of FV was measured.
- the samples, reagents and methods used are shown below. (Preparation of measurement sample)
- the hemoglobin solution 60 prepared in Example 1 was mixed with 37 L of the FV solution and 203 L of purified water to prepare a measurement sample.
- Sulfonic acid compound Sulfonic acid compound (SLS: manufactured by Nacalai Tesque, Inc.) 6.4 mM surfactant (e. Polyoxyethylene (9) lauryl ether) .85 g / L CHES-CHESNa buffer solution (pH 9.4) 40 mM MOPS-MOPSNa buffer (pH 9.4) 15 mM
- MOPS- MOPS ⁇ Na buffer pH 6.5
- 2,4-DNA manufactured by Wako Pure Chemical Industries
- ⁇ -NA manufactured by Wako Pure Chemical Industries
- p- NP manufactured by Wako Pure Chemical Industries, Ltd.
- Nacalai Tesque NaN0 2
- 2,4- DNH manufactured by Wako Pure Chemical Industries Ltd.
- the absorbance after 5 minutes was measured with a trade name of JCA-BM8 (manufactured by JEOL Ltd.).
- the measurement wavelength was 751 nm for the main wavelength and 805 nm for the sub wavelength.
- Example 2 As shown in Table 2 above, in Example 2, the combined use of the sulfonic acid compound and the various nitro compounds increased the absorbance indicating the FV amount in the sample as compared to the Comparative Example. Furthermore, the absorbance was further increased by adding twice the amount of the nitro compound. From these results, it can be seen that according to the present example, the effect of hemoglobin in the sample was eliminated by the sulfonic acid compound and the nitro compound.
- the measurement method of the present invention comprises the steps of: adding a sulfonic acid compound or a nitro compound to a sample to reduce a hemoglobin reducing substance in the sample; Since the effect of the measurement can be eliminated, highly reliable measurement can be performed. Therefore, the measurement method of the present invention can be applied to, for example, various analyzes in clinical medicine, and is particularly useful for measuring glycated proteins such as glycated hemoglobin in erythrocytes, which are important in diagnosing diabetes.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003235974A AU2003235974A1 (en) | 2002-06-14 | 2003-04-28 | Method of assay with sulfonic acid compound and nitro compound |
JP2004513779A JP4061366B2 (ja) | 2002-06-14 | 2003-04-28 | スルホン酸化合物およびニトロ化合物を用いた測定方法 |
EP03720984.8A EP1515144B2 (en) | 2002-06-14 | 2003-04-28 | Method of assay with sulfonic acid compound and nitro compound |
AT03720984T ATE445844T1 (de) | 2002-06-14 | 2003-04-28 | Testverfahren mit einer sulfonsäure- und einer nitroverbindung |
US10/517,853 US7354732B2 (en) | 2002-06-14 | 2003-04-28 | Method of assay with sulfonic acid compound and nitro compound |
DE60329679T DE60329679D1 (de) | 2002-06-14 | 2003-04-28 | Testverfahren mit einer sulfonsäure- und einer nitroverbindung |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002174896 | 2002-06-14 | ||
JP2002-174896 | 2002-06-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003107011A1 true WO2003107011A1 (ja) | 2003-12-24 |
Family
ID=29727998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/005486 WO2003107011A1 (ja) | 2002-06-14 | 2003-04-28 | スルホン酸化合物およびニトロ化合物を用いた測定方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US7354732B2 (ja) |
EP (1) | EP1515144B2 (ja) |
JP (1) | JP4061366B2 (ja) |
CN (1) | CN100394187C (ja) |
AT (1) | ATE445844T1 (ja) |
AU (1) | AU2003235974A1 (ja) |
DE (1) | DE60329679D1 (ja) |
WO (1) | WO2003107011A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8080423B2 (en) | 2004-08-05 | 2011-12-20 | Asahi Kasei Pharma Corporation | Reagent containing protease reaction promoter and/or colorant stabilizer |
WO2012020745A1 (ja) | 2010-08-11 | 2012-02-16 | 協和メデックス株式会社 | 糖化ヘモグロビンの測定方法 |
WO2012020744A1 (ja) | 2010-08-11 | 2012-02-16 | 協和メデックス株式会社 | 糖化ヘモグロビンの測定方法 |
US8268017B2 (en) | 2007-02-22 | 2012-09-18 | Asahi Kasei Pharma Corporation | Method for stabilizing leuco-type colorant |
WO2012173185A1 (ja) | 2011-06-17 | 2012-12-20 | 協和メデックス株式会社 | 糖化ヘモグロビンの測定方法、測定試薬、及び、測定キット |
WO2013118743A1 (ja) * | 2012-02-09 | 2013-08-15 | 協和メデックス株式会社 | アスコルビン酸の影響抑制方法 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003235975A1 (en) * | 2002-07-17 | 2004-02-02 | Arkray, Inc. | Method of decomposing protein with sulfonic acid compound |
KR20070026404A (ko) * | 2004-03-17 | 2007-03-08 | 다이이치 가가쿠 야쿠힝 가부시키가이샤 | 피산화성 정색시약의 안정화 방법 |
US20090075284A1 (en) * | 2006-09-19 | 2009-03-19 | The Regents Of The University Of Michigan | Metabolomic profiling of prostate cancer |
KR101207418B1 (ko) * | 2012-02-10 | 2012-12-04 | 주식회사 아이센스 | 효소법을 이용하는 당화혈색소 정량분석용 용혈시약 조성물 |
CN103483229B (zh) * | 2013-09-12 | 2015-06-17 | 杭州隆基生物技术有限公司 | 一种atp释放剂及包含该释放剂的细菌快速检测试剂 |
KR102646392B1 (ko) * | 2015-03-31 | 2024-03-11 | 에이껜 가가꾸 가부시끼가이샤 | 헴 단백질의 보존액 및 헴 단백질의 안정화 방법 |
CN105295441B (zh) * | 2015-11-20 | 2018-05-08 | 三诺生物传感股份有限公司 | 一种显色剂的稳定剂及其应用 |
EP3492529A4 (en) * | 2016-07-29 | 2020-12-16 | Hitachi Chemical Diagnostics Systems Co., Ltd. | PROCESS FOR PRESERVING AN AQUEOUS SOLUTION CONTAINING A LEUCO-TYPE CHROMOGEN |
JP7056577B2 (ja) * | 2016-11-30 | 2022-04-19 | 東洋紡株式会社 | ヘモグロビンの糖化率測定方法 |
CN113311465B (zh) * | 2021-04-08 | 2022-04-19 | 中国辐射防护研究院 | 一种样品中Pu同位素和Np-237含量的联合分析方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54123096A (en) * | 1978-02-13 | 1979-09-25 | Miles Lab | Method and test implement for measuring oxidizable substanceand method of making said test implement |
JPS6184A (ja) * | 1984-06-09 | 1986-01-06 | Wako Pure Chem Ind Ltd | 新規なテトラゾリウム化合物 |
JP2000093199A (ja) * | 1998-09-28 | 2000-04-04 | Lifescan Inc | テトラゾリウム化合物に基づく診断 |
JP2001292795A (ja) * | 2000-02-25 | 2001-10-23 | Lifescan Inc | テトラゾリウム化合物に基づく診断 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1114411A (en) * | 1912-02-27 | 1914-10-20 | Stephen T Stuver | Shredding-machine. |
US2271175A (en) * | 1938-12-30 | 1942-01-27 | Mantelet & Boucher | Portable rotary grater |
US2487597A (en) * | 1946-09-13 | 1949-11-08 | Archer M Sampson | Rotary disk shaver with axially manually fed pusher |
FR2230320B3 (ja) * | 1973-05-23 | 1976-05-14 | Moulinex Sa | |
US4081145A (en) * | 1977-04-18 | 1978-03-28 | Diker-Moe Associates | Food cutting machine |
US4214715A (en) * | 1978-08-15 | 1980-07-29 | M. H. Graham Corporation | Rotary food cutting apparatus |
US4219165A (en) * | 1978-10-10 | 1980-08-26 | Saladmaster, Inc. | Attachment for food cutters |
US4227656A (en) * | 1978-12-22 | 1980-10-14 | Hobart Corporation | Vegetable slicer |
DE3012368C2 (de) * | 1980-03-29 | 1982-04-15 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren und diagnostische Mittel zum Nachweis von Redox-Reaktionen |
US4310626A (en) | 1980-06-02 | 1982-01-12 | Miles Laboratories, Inc. | Interference-resistant composition, device and method for determining a peroxidatively active substance in a test sample |
JPS57161650A (en) | 1981-03-16 | 1982-10-05 | Miles Lab | Test device for measuring peroxidizing active material in sample and manufacture thereof |
ZA841185B (en) | 1983-03-28 | 1984-09-26 | Miles Lab | Ascorbate interference-resistant composition,device and method for the determination of peroxidatively active substances |
US4587220A (en) * | 1983-03-28 | 1986-05-06 | Miles Laboratories, Inc. | Ascorbate interference-resistant composition, device and method for the determination of peroxidatively active substances |
JPS60168050A (ja) | 1984-02-10 | 1985-08-31 | Wako Pure Chem Ind Ltd | ヘモグロビンの影響回避方法 |
US4755472A (en) * | 1986-01-16 | 1988-07-05 | Miles Inc. | Stable composition for the determination of peroxidatively active substances |
US4884755A (en) * | 1988-08-30 | 1989-12-05 | Presto Industries, Inc. | Food processor |
JPH0269644A (ja) | 1988-09-05 | 1990-03-08 | Toshiba Corp | セラミックス体の非破壊検査方法 |
US4954451A (en) * | 1989-06-26 | 1990-09-04 | Miles Inc. | Agent for diminishing ascorbate interference in reagent systems and method relating thereto |
US5148995A (en) * | 1991-08-01 | 1992-09-22 | Hurst Richard F | Apparatus for decomposting compressed tablets |
US5840701A (en) * | 1993-08-16 | 1998-11-24 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
BR9407833A (pt) * | 1993-10-14 | 1997-05-13 | Procter & Gamble | Composições alvejantes compreendendo enzimas protease |
DE59507049D1 (de) * | 1995-03-01 | 1999-11-18 | Weigert Chem Fab | Reinigungsmittel für chirurgische Instrumente |
JP2945861B2 (ja) * | 1995-11-30 | 1999-09-06 | タナシン電機株式会社 | テープレコーダの動作切換装置 |
JPH09185021A (ja) | 1995-12-28 | 1997-07-15 | Toray Ind Inc | コンタクトレンズ用洗浄保存液 |
US5660341A (en) * | 1996-02-15 | 1997-08-26 | The Pampered Chef, Ltd. | Rotary grater |
JPH10210967A (ja) | 1996-11-29 | 1998-08-11 | Ajinomoto Co Inc | 高活性変異株及びそれを用いる蛋白加水分解物の製造法 |
EP0921198B1 (en) * | 1997-04-24 | 2006-07-19 | ARKRAY, Inc | Method for enzymatically assaying saccharification protein |
JPH11196897A (ja) | 1998-01-09 | 1999-07-27 | Kdk Corp | 糖化タンパク質の測定方法及び測定装置 |
US6352835B1 (en) | 1998-11-17 | 2002-03-05 | Kyoto Daiichi Kagaku Co. Ltd. | Method of measuring substance in sample using a redox reaction |
USRE46105E1 (en) * | 2000-07-14 | 2016-08-16 | Arkray, Inc. | Method of selectively determining glycated hemoglobin |
US6790665B2 (en) * | 2000-09-28 | 2004-09-14 | Arkray, Inc. | Method of quantifying hemoglobin and method of measuring glycation ratio of hemoglobin |
WO2002027331A1 (fr) | 2000-09-28 | 2002-04-04 | Arkray, Inc. | Methode d'analyse utilisant une reaction d'oxydo-reduction |
US20020173043A1 (en) * | 2001-04-04 | 2002-11-21 | Eddine Merabet | Cyanide-free reagent, and method for detecting hemoglobin |
-
2003
- 2003-04-28 AU AU2003235974A patent/AU2003235974A1/en not_active Abandoned
- 2003-04-28 DE DE60329679T patent/DE60329679D1/de not_active Expired - Lifetime
- 2003-04-28 AT AT03720984T patent/ATE445844T1/de not_active IP Right Cessation
- 2003-04-28 WO PCT/JP2003/005486 patent/WO2003107011A1/ja active Application Filing
- 2003-04-28 CN CNB038138220A patent/CN100394187C/zh not_active Expired - Lifetime
- 2003-04-28 EP EP03720984.8A patent/EP1515144B2/en not_active Expired - Lifetime
- 2003-04-28 US US10/517,853 patent/US7354732B2/en not_active Expired - Lifetime
- 2003-04-28 JP JP2004513779A patent/JP4061366B2/ja not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54123096A (en) * | 1978-02-13 | 1979-09-25 | Miles Lab | Method and test implement for measuring oxidizable substanceand method of making said test implement |
JPS6184A (ja) * | 1984-06-09 | 1986-01-06 | Wako Pure Chem Ind Ltd | 新規なテトラゾリウム化合物 |
JP2000093199A (ja) * | 1998-09-28 | 2000-04-04 | Lifescan Inc | テトラゾリウム化合物に基づく診断 |
JP2001292795A (ja) * | 2000-02-25 | 2001-10-23 | Lifescan Inc | テトラゾリウム化合物に基づく診断 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8080423B2 (en) | 2004-08-05 | 2011-12-20 | Asahi Kasei Pharma Corporation | Reagent containing protease reaction promoter and/or colorant stabilizer |
US8268017B2 (en) | 2007-02-22 | 2012-09-18 | Asahi Kasei Pharma Corporation | Method for stabilizing leuco-type colorant |
WO2012020745A1 (ja) | 2010-08-11 | 2012-02-16 | 協和メデックス株式会社 | 糖化ヘモグロビンの測定方法 |
WO2012020744A1 (ja) | 2010-08-11 | 2012-02-16 | 協和メデックス株式会社 | 糖化ヘモグロビンの測定方法 |
US9090931B2 (en) | 2010-08-11 | 2015-07-28 | Kyowa Medex Co., Ltd | Method for measuring glycated hemoglobin |
WO2012173185A1 (ja) | 2011-06-17 | 2012-12-20 | 協和メデックス株式会社 | 糖化ヘモグロビンの測定方法、測定試薬、及び、測定キット |
JPWO2012173185A1 (ja) * | 2011-06-17 | 2015-02-23 | 協和メデックス株式会社 | 糖化ヘモグロビンの測定方法、測定試薬、及び、測定キット |
WO2013118743A1 (ja) * | 2012-02-09 | 2013-08-15 | 協和メデックス株式会社 | アスコルビン酸の影響抑制方法 |
CN104093852A (zh) * | 2012-02-09 | 2014-10-08 | 协和梅迪克斯株式会社 | 抑制抗坏血酸的影响的方法 |
JPWO2013118743A1 (ja) * | 2012-02-09 | 2015-05-11 | 協和メデックス株式会社 | アスコルビン酸の影響抑制方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2003235974A1 (en) | 2003-12-31 |
EP1515144B2 (en) | 2013-04-24 |
EP1515144B1 (en) | 2009-10-14 |
DE60329679D1 (de) | 2009-11-26 |
ATE445844T1 (de) | 2009-10-15 |
EP1515144A4 (en) | 2006-05-17 |
US7354732B2 (en) | 2008-04-08 |
EP1515144A1 (en) | 2005-03-16 |
CN100394187C (zh) | 2008-06-11 |
CN1662818A (zh) | 2005-08-31 |
US20050221415A1 (en) | 2005-10-06 |
JPWO2003107011A1 (ja) | 2005-10-13 |
JP4061366B2 (ja) | 2008-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1002874B1 (en) | Redox reactions for analyte determination using tetrazolium compounds | |
WO2003107011A1 (ja) | スルホン酸化合物およびニトロ化合物を用いた測定方法 | |
JP2010011876A (ja) | 酸化還元反応を用いた糖化タンパク質の測定方法および測定キット | |
EP1329722A1 (en) | Assay method with the use of redox reaction | |
JP4045322B2 (ja) | 酸化還元反応を用いた測定方法 | |
WO2002027330A1 (fr) | Procede de quantification d'hemoglobine et procede de mesure du taux de glycation d'hemoglobine | |
JP2007147630A (ja) | スルホン酸化合物およびニトロ化合物を用いた測定方法 | |
US8021855B2 (en) | Method of decomposing protein with sulfonic acid compound | |
WO2002027012A1 (fr) | Procede de production de produits de degradation de proteines | |
EP1515143B1 (en) | Method of assay by oxidation-reduction reaction with formazan | |
US7226790B2 (en) | Method for measurement using sodium azide | |
JP4250693B2 (ja) | 酸化還元反応を用いた測定方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004513779 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038138220 Country of ref document: CN Ref document number: 10517853 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003720984 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003720984 Country of ref document: EP |